Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Net Margin (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Net Margin for 6 consecutive years, with 3029.64% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin fell 207276.0% to 3029.64% in Q4 2025 year-over-year; TTM through Dec 2025 was 794.04%, a 31847.0% decrease, with the full-year FY2025 number at 794.04%, down 31847.0% from a year prior.
  • Net Margin was 3029.64% for Q4 2025 at Kymera Therapeutics, down from 2973.05% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 30.01% in Q4 2023 to a low of 3029.64% in Q4 2025.
  • A 5-year average of 758.56% and a median of 408.32% in 2023 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: skyrocketed 51299bps in 2021, then crashed -207276bps in 2025.
  • Kymera Therapeutics' Net Margin stood at 133.16% in 2021, then plummeted by -62bps to 216.03% in 2022, then surged by 86bps to 30.01% in 2023, then plummeted by -3089bps to 956.88% in 2024, then tumbled by -217bps to 3029.64% in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Net Margin are 3029.64% (Q4 2025), 2973.05% (Q3 2025), and 667.6% (Q2 2025).